Topokine Therapeutics Receives Financing from Schooner Capital

Topokine Therapeutics, a Newton, MA-based clinical-stage biotechnology company developing therapies for dermatology and medical aesthetics, received a financing from Schooner Capital.

The amount of the transaction was not disclosed.

Led by Murat Kalayoglu, MD, PhD, President and CEO, Topokine Therapeutics is advancing XAF5 Gel, a skin cream being developed for local reduction of excess subcutaneous fat.

The company intends to use the proceeds to develop its pipeline, including XAF5 Gel, which is now in a Phase I Clinical Trial whose results are expected in the first half of 2013.



Join the discussion